Risvan® (risperidone) for extended-release injectable suspension
Approval Date: Mar 2024
A long-acting, atypical antipsychotic indicated for the treatment of schizophrenia
Exxua™ (gepirone) extended-release tablets
Approval Date: Sep 2023
Indicated for the treatment of major depressive disorder (MDD), a first-in-class drug that selectively targets the serotonin 1A receptor
Abilify Asimtufii® (aripiprazole)
Approval Date: Apr 2023
Indicated for the treatment of schizophrenia or as maintenance monotherapy treatment of bipolar I disorder
Uzedy™ (risperidone) extended-release injectable suspension
Approval Date: Apr 2023
Indicated for the treatment of schizophrenia in adults
Rexulti® (brexpiprazole) tablets
Approval Date: Aug 2022
Indicated for the adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)
Auvelity™ (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets
Approval Date: Aug 2022
For the treatment of major depressive disorder, this antidepressant is notable for producing antidepressant results within one week
Igalmi™ (dexmedetomidine) sublingual film
Approval Date: Apr 2022
Indicated for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder
Paxil™ (paroxetine) oral suspension
Approval Date: Sep 2021
Indicated for the treatment of major depressive disorder, obsessive compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, and PTSD
Trintellix® (vortioxetine) tablets
Approval Date: Sep 2021
Indicated for the treatment of major depressive disorder (MDD)
Loreev XR (lorazepam) extended release capsules
Approval Date: Sep 2021
For the treatment of anxiety disorders in adults receiving stable, evenly divided, three times daily dosing with lorazepam tablets
